Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 6, 2011, Pages 965-973

  Kaufmann, Roland ^a   Mußbach, Franziska ^a   Henklein, Petra ^b   Settmacher, Utz ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Calcium signaling; Hepatocellular carcinoma; Mitogen activated protein kinases; PAR2; Proteinase activated receptor 2

Indexed keywords

CALCIUM ION; EDETIC ACID; ENZYME ANTIBODY; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE ACTIVATED RECEPTOR 2; SMALL INTERFERING RNA; THAPSIGARGIN; TRYPSIN;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL INVASION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR CALCIUM; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; WESTERN BLOTTING;

CALCIUM; CALCIUM SIGNALING; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; OLIGOPEPTIDES; RECEPTOR, PAR-2; TRYPSIN;

EID: 79959688139     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0961-1     Document Type: Article

References (41)

1. Berridge M, Bootman M, Roderick H (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4:517-529 (Pubitemid 36773404)
2. Bocheva G, Rattenholl A, Kempkes C, Goerge T, Lin C, D'Andrea M et al (2009) Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. J Invest Dermatol 129(7): 1816-1823
3. Bootman M, Collins T, Peppiatt C, Prothero L, MacKenzie L, De Smet P et al (2001) Calcium signalling - an overview. Semin Cell Dev Biol 12:3-10 (Pubitemid 32147100)
4. Bosch F, Ribes J, Cléries R, Díaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191-211
5. Calvisi D, Pascale R, Feo F (2007) Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2:217-236 (Pubitemid 47558825)
6. Clapham D (2007) Calcium signaling. Cell 131:1047-1058
7. Coelho A, Ossovskaya V, Bunnett N (2003) Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents 1:61-72
8. Covic L, Gresser A, Talavera J, Swift S, Kuliopulos A (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99:643-648 (Pubitemid 34106565)
9. Darmoul D, Gratio V, Devaud H, Laburthe M (2004) Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279: 20927-20934 (Pubitemid 38656491)
10. Ge L, Shenoy S, Lefkowitz R, DeFea K (2004) Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem 279:55419-55424 (Pubitemid 40066542)
11. Gearhart T, Bouchard M (2010) The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol 84:2675-2686
12. Gee K, Brown K, Chen W, Bishop-Stewart J, Gray D, Johnson I (2000) Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 27:97-106 (Pubitemid 30150798)
13. Ghali J, Smith W, Torre-Amione G, Haynos W, Rayburn B, Amato A et al (2007) A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 99:47A-56A
14. Grab D, Garcia-Garcia J, Nikolskaia O, Kim Y, Brown A, Pardo C (2009) Protease activated receptor signalling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis 3:e479
15. Grynkiewicz G, Poenie M, Tsien R (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450 (Pubitemid 15114340)
16. Hjortoe G, Petersen L, Albrektsen T, Sorensen B, Norby P, Mandal S et al (2004) Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103: 3029-3037 (Pubitemid 38451676)
17. Hodges R, Horikawa Y, Rios J, Shatos M, Dartt D (2007) Effect of protein kinase C and Ca(2+) on p42/p44 MAPK, Pyk2, and Src activation in rat conjunctival goblet cells. Exp Eye Res 85:836-844
18. Hollenberg M, Renaux B, Hyun E, Houle S, Vergnolle N, Saifeddine M et al (2008) Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: binding and visualization. J Pharmacol Exp Ther 326:453-462
19. Huynh H, Nguyen T, Chow K, Tan P, Soo K, Tran E (2003) Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19
20. Jaffe L (2005) A calcium-based theory of carcinogenesis. Adv Cancer Res 94:231-263
21. Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N (2003) MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci 73:2817-2829 (Pubitemid 37153356)
22. Kanno H, Horikawa Y, Hodges R, Zoukhri D, Shatos M, Rios J et al (2003) Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am J Physiol Cell Physiol 284:C988-C998 (Pubitemid 36336955)
23. Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J (2002) PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 20:177-180
24. Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M (2007) Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 211:699-707 (Pubitemid 46683038)
25. Kaufmann R, Oettel C, Horn A, Halbhuber K, Eitner A, Krieg R (2009) Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis 30:1487-1496
26. Kijima Y, Ogunbunmi E, Fleischer S (1991) Drug action of thapsigargin on the Ca2+ pump protein of sarcoplasmic reticulum. J Biol Chem 266:22912-22918 (Pubitemid 21908738)
27. Klein P, Schmidt C, Wiesenauer C, Choi J, Gage E, Yip-Schneider M (2006) The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 8:1-8
28. McGuire J, Saifeddine M, Triggle C, Sun K, Hollenberg M (2004) 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. J Pharmacol Exp Ther 309: 1124-1131 (Pubitemid 38669700)
29. Monteith G, McAndrew D, Faddy H, Roberts-Thomson S (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7:519-530 (Pubitemid 46985398)
30. Morris D, Ding Y, Ricks T, Gullapalli A, Wolfe B, Trejo J (2006) Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66:307-314 (Pubitemid 43166037)
31. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J (1994) Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91:9208-9212 (Pubitemid 24297883)
32. Ossovskaya V, Bunnett N (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579-621 (Pubitemid 38365493)
33. Ramachandran R, Hollenberg M (2008) Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153(Suppl 1):S263-S282 (Pubitemid 351340983)
34. Rattenholl A, Seeliger S, Buddenkotte J, Schön M, Schön M, Ständer S et al (2007) Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol 127: 2245-2252 (Pubitemid 47258489)
35. Roberts L, Gores G (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25: 212-225 (Pubitemid 40781073)
36. Shi X, Gangadharan B, Brass L, Ruf W, Mueller B (2004) Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2:395-402 (Pubitemid 39031073)
37. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y et al (2004) A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 24:1401-1406
38. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N et al (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43 (Pubitemid 40209385)
39. Thastrup O, Cullen P, Drøbak B, Hanley M, Dawson A (1990) Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci USA 87:2466-2470
40. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M et al (2004) Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24:432-436 (Pubitemid 40484556)
41. Versteeg H, Schaffner F, Kerver M, Petersen H, Ahamed J, Felding-Habermann B (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:190-199